CMC gets the letter.
The warning signs often started upstream.
The batch record that drifted. The OOS that wasn't fully resolved. The validation evidence that no longer matched the operating state.
A CRL is late evidence. The underlying quality signal can exist months earlier — across records no single system evaluates together. That's why we built Clinplex.
Built by the people who lived the fracture.
Engineering and Quality — two founders from two different rooms, now building the wire between them.
18 years inside FDA-regulated operations. Biologics manufacturing at J&J. Federal compliance at Leidos / NCI Frederick. Led CAPA cycles, 483 responses, and audit remediation.
12+ years building systems at scale. Platforms serving 100M+ daily users. Carnegie Mellon. Owns AI agent infrastructure, the 150+ framework knowledge base, and the Part 11 compliance backbone.
It was all in the records. Nothing read across them.
CRL cites CMC. Root cause isn't there. It's in the batch record that drifted. The OOS nobody closed out. The validation that passed on paper.
Your systems of record are getting smarter. The problem is still the boundary between them.
Veeva, MasterControl, ValGenesis and other regulated platforms increasingly bring AI into the workflows they manage. Clinplex is designed for a different operating boundary: independently evaluating regulatory adequacy across evidence that may span Quality, LIMS, validation, manufacturing, CMC and submissions—regardless of where those records live.
The systems keep their workflows. Clinplex reads across the boundary between them.
By the time FDA flags it, you've already lost 12 to 18 months.
Late-stage applications delayed by manufacturing and CMC — not failed clinical efficacy.
Public CRLs show how an otherwise viable application can enter another review cycle because of manufacturing, facility or CMC deficiencies.
Facility-related and data-integrity concerns at a drug-substance manufacturing site prevented FDA from reliably interpreting relevant manufacturing datasets. Efficacy and safety had already been established.
Container-closure incompatibility — glass particles found in clinical batches. Exactly the kind of upstream quality signal Clinplex is built to connect before submission.
of 202 FDA Complete Response Letters released for applications submitted 2020–2024 and subsequently approved involved quality or manufacturing deficiencies.
Figures reflect Clinplex and third-party analyses of public FDA Complete Response Letter data; methodology available on request. CRL examples are drawn from public FDA communications and company disclosures.
Built with the people who know what inspection-ready means.
Advised by specialists across validation, CMC, nonclinical review, Quality operations and global regulatory strategy.
Immunologist at the NIH, leading research on cytokine therapeutics. Decade+ across preclinical and clinical immunology, biomarker development, and vaccine responses.
Inventor on multiple patents. Associate Editor, Frontiers in Immunology.
Associate Validation Manager at MacroGenics. 20+ years in validation, QC, and regulatory compliance — risk-based validation, equipment qualification, CSV, and 21 CFR Part 11.
Previously Senior QC Analyst at AstraZeneca / MedImmune. BS Biology, Towson. Advises on validation lifecycle and regulatory audits.
CMC Regulatory Affairs Associate Director at AstraZeneca. 15+ years filing global submissions across mAbs, CAR-T, oncology, and vaccines — to FDA, EMA, and global authorities.
Advises on regulatory strategy, CMC documentation, and submission readiness.
Lead, Regulatory Affairs CMC at Astellas Pharma. Manages global clinical trial submissions IND through BLA.
Advises on CMC submission workflows and global health authority expectations.
Senior CMC regulatory leader at a top-10 global pharma, delivering strategy across the full product lifecycle.
Quality operations leader at a cell & gene therapy biotech, with 25+ years across GMP, GCP, and GLP.
Affiliations are listed for background only. Advisors participate in an individual capacity; Clinplex is not endorsed by any listed organization, the FDA, NIH, or any current or former employer.
See the fracture
in your own records.
Clinplex is the AI regulatory intelligence layer that augments your QMS. The QMS is the system of record. Clinplex is the intelligence layer the QMS was never designed to provide.
Send one closed deviation, its CAPA and the governing SOP. Clinplex evaluates whether the three records support the same regulatory conclusion.